Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 3Unknown 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 6Myeloid 4Sarcoma 2Plasma cell 2Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Mastocytosis 4Pruritus 2Piebaldism 2Mastocytosis, Systemic 2Blushing 2

Interventions

Azacitidine 68nilotinib 50Imatinib Mesylate 50ruxolitinib 42Dasatinib 25venetoclax 22Decitabine 20bosutinib 18asciminib 17Cytarabine 15ponatinib 10decitabine and cedazuridine drug combination 10AP 1903 reagent 10Cyclophosphamide 9fludarabine 8Hydroxyurea 8navitoclax 6ON 01910 6sabatolimab 5pevonedistat 5mocetinostat 5luspatercept 5itacitinib 5imetelstat 5givinostat hydrochloride 5givinostat 5fludarabine phosphate 5avapritinib 5Mycophenolic Acid 5Lenalidomide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × masitinib × Myeloid × Clear all
NCT04333108 2023-05-06

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

AB Science

Phase 3 Unknown
140 enrolled
Myeloid

Blushing, Mastocytosis, Pruritus, Piebaldism, Mastocytosis, Systemic

NCT00814073 2019-12-03

AB06006

AB Science

Phase 3 Completed
135 enrolled
Myeloid

Blushing, Mastocytosis, Pruritus, Piebaldism, Mastocytosis, Systemic

NCT00831974 2018-12-11

Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis

AB Science

Phase 2 Completed
23 enrolled
Myeloid

Mastocytosis

NCT01266369 2018-12-10

Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation

AB Science

Phase 2 Completed
21 enrolled
Myeloid

Mastocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡